Crux, the first benefits platform partnering with big pharma and employers of all sizes to expand transparent and affordable access to transformative quality-of-life (QoL) medications, announced its public launch with $6.5 million in pre-seed funding from Red Cell Partners, a venture studio that builds rapidly scalable, technology-led companies that are bringing revolutionary advancements to market in critical industries like healthcare.